[Multi-modality therapy based on surgery in advanced non-small cell lung cancer patients: Analysis of 51 cases].
BACKGROUND
At the time of being diagnosed as non-small cell lung cancer (NSCLC), 65%-70% of the patients are at the advanced stage (stage III, IV). It is believed that the multi-modality therapy has a better efficacy than mono-therapy. The aim of this study is to evaluate the efficacy of multi-modality therapy based on surgery in advanced NSCLC.


METHODS
The clinicopathological data were retrospectively reviewed from 51 stage IIIB-IV NSCLC patients, who underwent surgery and multiple modality therapy during 1995 to 2003 in the department of Thoracic Surgery of PUMC Hospital. The survival of patients was analyzed.


RESULTS
The overall 1- and 3-year survival rate was 86.35%±5.21% and 52.96%±8.83%, respectively. The median survival time was 37.0 months.


CONCLUSIONS
The multi-modality therapy based on surgery could improve the survival of operable patients with advanced NSCLC.
Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, P.R.China.
Huiqin
H
Guo
Jie
J
Sun
Yiming
Y
Zhu
Zhili
Z
Cao